ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc (CYCN)

2.67
-0.15
(-5.32%)
Closed 01 March 8:00AM
2.67
0.00
( 0.00% )
Pre Market: 11:00PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.67
Bid
2.55
Offer
3.10
Volume
-
0.00 Day's Range 0.00
1.27 52 Week Range 9.4699
Market Cap
Previous Close
2.67
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
2,217,111
Shares Outstanding
2,710,096
Dividend Yield
-
PE Ratio
-1.37
Earnings Per Share (EPS)
-1.94
Revenue
-
Net Profit
-5.26M

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of nex... Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Boston, Massachusetts, USA
Founded
-
Cyclerion Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CYCN. The last closing price for Cyclerion Therapeutics was US$2.67. Over the last year, Cyclerion Therapeutics shares have traded in a share price range of US$ 1.27 to US$ 9.4699.

Cyclerion Therapeutics currently has 2,710,096 shares in issue. The market capitalisation of Cyclerion Therapeutics is US$7.24 million. Cyclerion Therapeutics has a price to earnings ratio (PE ratio) of -1.37.

CYCN Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0101-0.3768516100152.68012.992.5108993392.74711174CS
4-1.634-37.96468401494.3046.252.510816839635.12524399CS
12-1.1381-29.88629500283.80816.252.322171114.22017219CS
26-0.26-8.873720136522.939.46991.2725335064.90060815CS
52-0.49-15.50632911393.169.46991.2712484534.89727118CS
156-21.93-89.146341463424.6281.275037386.23517018CS
260-91.73-97.171610169594.4179.21.2751572133.96393228CS

CYCN - Frequently Asked Questions (FAQ)

What is the current Cyclerion Therapeutics share price?
The current share price of Cyclerion Therapeutics is US$ 2.67
How many Cyclerion Therapeutics shares are in issue?
Cyclerion Therapeutics has 2,710,096 shares in issue
What is the market cap of Cyclerion Therapeutics?
The market capitalisation of Cyclerion Therapeutics is USD 7.24M
What is the 1 year trading range for Cyclerion Therapeutics share price?
Cyclerion Therapeutics has traded in the range of US$ 1.27 to US$ 9.4699 during the past year
What is the PE ratio of Cyclerion Therapeutics?
The price to earnings ratio of Cyclerion Therapeutics is -1.37
What is the reporting currency for Cyclerion Therapeutics?
Cyclerion Therapeutics reports financial results in USD
What is the latest annual profit for Cyclerion Therapeutics?
The latest annual profit of Cyclerion Therapeutics is USD -5.26M
What is the registered address of Cyclerion Therapeutics?
The registered address for Cyclerion Therapeutics is 155 FEDERAL STREET, SUITE 700, BOSTON, MASSACHUSETTS, 02110
What is the Cyclerion Therapeutics website address?
The website address for Cyclerion Therapeutics is www.cyclerion.com
Which industry sector does Cyclerion Therapeutics operate in?
Cyclerion Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BTOGBit Origin Ltd
US$ 0.9679
(431.81%)
81.96M
ACONAclarion Inc
US$ 6.2794
(87.44%)
15.81M
FTFTFuture FinTech Group Inc
US$ 0.3126
(54.75%)
56.7M
BSCUInvesco BulletShares 2030 Corporate Bond ETF
US$ 24.99
(50.45%)
3
LGHLWLion Group Holding Ltd
US$ 0.0093
(38.81%)
10
BSCSInvesco Bulletshares 2028 Corporate Bond ETF
US$ 10.01
(-50.79%)
1
LXRXLexicon Pharmaceuticals Inc
US$ 0.367401
(-47.48%)
11.32M
NVNINVNI Group Ltd
US$ 0.5741
(-43.16%)
8.07M
SYRSSyros Pharmaceuticals Inc
US$ 0.085
(-40.64%)
1.09M
CTKBCytek Biosciences Inc
US$ 2.71
(-39.64%)
4
BTOGBit Origin Ltd
US$ 0.9679
(431.81%)
81.96M
FTFTFuture FinTech Group Inc
US$ 0.3126
(54.75%)
56.7M
TRNRInteractive Strength Inc
US$ 3.14
(22.18%)
19.93M
ARBKArgo Blockchain PLC
US$ 0.434
(6.53%)
19.36M
HOLOMicroCloud Hologram Inc
US$ 1.16
(19.58%)
16.65M

CYCN Discussion

View Posts
Monksdream Monksdream 20 hours ago
CYCN 10 Q due MONDAY 3/3

๐Ÿ‘๏ธ0
glenn1919 glenn1919 3 weeks ago
CYCN................................................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
georgie18 georgie18 4 weeks ago
CYCN...$6.05...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 31425

Monday, February 03, 2025 2:09:38 PM

Post#
31429
of 31433
CYCN...$5.68...HOD...🥳...off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 673136

Monday, February 03, 2025 1:54:57 PM

Post#
673150
of 673155
CYCN...$5.13 On the breakout...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 31398

Monday, February 03, 2025 12:30:04 PM

Post#
31405
of 31424
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...

georgie18

Member Level
Re: georgie18 post# 673098

Monday, February 03, 2025 12:09:45 PM

Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyโ€™s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

โ€œThese agreements demonstrate Cyclerionโ€™s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,โ€ said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. โ€œThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.โ€ Graul continued, โ€œCyclerionโ€™s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.โ€

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionโ€™s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
๐Ÿ‘๏ธ0
georgie18 georgie18 4 weeks ago
CYCN...$5.68...HOD...🥳...off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 673136

Monday, February 03, 2025 1:54:57 PM

Post#
673150
of 673155
CYCN...$5.13 On the breakout...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 31398

Monday, February 03, 2025 12:30:04 PM

Post#
31405
of 31424
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...

georgie18

Member Level
Re: georgie18 post# 673098

Monday, February 03, 2025 12:09:45 PM

Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyโ€™s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

โ€œThese agreements demonstrate Cyclerionโ€™s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,โ€ said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. โ€œThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.โ€ Graul continued, โ€œCyclerionโ€™s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.โ€

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionโ€™s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
๐Ÿ‘๏ธ0
georgie18 georgie18 4 weeks ago
CYCN...$5.13 On the breakout...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 31398

Monday, February 03, 2025 12:30:04 PM

Post#
31405
of 31424
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...

georgie18

Member Level
Re: georgie18 post# 673098

Monday, February 03, 2025 12:09:45 PM

Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyโ€™s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

โ€œThese agreements demonstrate Cyclerionโ€™s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,โ€ said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. โ€œThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.โ€ Graul continued, โ€œCyclerionโ€™s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.โ€

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionโ€™s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
๐Ÿ‘๏ธ0
georgie18 georgie18 4 weeks ago
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...

georgie18

Member Level
Re: georgie18 post# 673098

Monday, February 03, 2025 12:09:45 PM

Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyโ€™s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

โ€œThese agreements demonstrate Cyclerionโ€™s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,โ€ said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. โ€œThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.โ€ Graul continued, โ€œCyclerionโ€™s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.โ€

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionโ€™s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
๐Ÿ‘๏ธ0
georgie18 georgie18 4 weeks ago
CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyโ€™s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

โ€œThese agreements demonstrate Cyclerionโ€™s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,โ€ said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. โ€œThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.โ€ Graul continued, โ€œCyclerionโ€™s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.โ€

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionโ€™s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
๐Ÿ‘๏ธ0
glenn1919 glenn1919 4 weeks ago
CYCN......................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
tw0122 tw0122 4 weeks ago
One more round $4.56 + 16% 2m floater take profits  otw up $4.70s
๐Ÿ‘๏ธ0
georgie18 georgie18 4 weeks ago
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyโ€™s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

โ€œThese agreements demonstrate Cyclerionโ€™s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,โ€ said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. โ€œThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.โ€ Graul continued, โ€œCyclerionโ€™s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.โ€

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionโ€™s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
๐Ÿ‘๏ธ0
georgie18 georgie18 1 month ago
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyโ€™s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

โ€œThese agreements demonstrate Cyclerionโ€™s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,โ€ said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. โ€œThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.โ€ Graul continued, โ€œCyclerionโ€™s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.โ€

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionโ€™s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
๐Ÿ‘๏ธ0
georgie18 georgie18 1 month ago
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyโ€™s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

โ€œThese agreements demonstrate Cyclerionโ€™s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,โ€ said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. โ€œThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.โ€ Graul continued, โ€œCyclerionโ€™s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.โ€

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionโ€™s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
๐Ÿ‘๏ธ0
tw0122 tw0122 1 month ago
Ring the register $4.07$$$$
๐Ÿ‘๏ธ0
glenn1919 glenn1919 1 month ago
CYCN.......................................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
georgie18 georgie18 1 month ago
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyโ€™s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

โ€œThese agreements demonstrate Cyclerionโ€™s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,โ€ said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. โ€œThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.โ€ Graul continued, โ€œCyclerionโ€™s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.โ€

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionโ€™s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
๐Ÿ‘๏ธ0
glenn1919 glenn1919 1 month ago
cycn.........................................................a/h
๐Ÿ‘๏ธ0
georgie18 georgie18 2 months ago
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Companyโ€™s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

โ€œThese agreements demonstrate Cyclerionโ€™s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,โ€ said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. โ€œThese newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.โ€ Graul continued, โ€œCyclerionโ€™s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.โ€

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerionโ€™s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.
๐Ÿ‘๏ธ0
LowFloatLopes LowFloatLopes 3 months ago
That's usually exactly what I do sometimes I'll gamble though and stay in longer like I did today :) good strategy 👍🏼
👍️ 1
Strukture Strukture 3 months ago
I just sell the top of the rips buy the dips so long as the trend stays bullish if it goes para after i sell thats ok too
๐Ÿ‘๏ธ0
LowFloatLopes LowFloatLopes 3 months ago
Right on cue lol 
๐Ÿ‘๏ธ0
LowFloatLopes LowFloatLopes 3 months ago
IM still holding from that past.. I'm feeling a pop 29 or 10 in the next hour
๐Ÿ‘๏ธ0
trader59 trader59 3 months ago
Automated wash trading, brazen manipulation of the PPS. The O/S is 2.7M shares, which means that each and every share issued and outstanding has changed hands, on average, over 40 times today. Once they turn their computers off, folks will be trapped with grossly overpriced bags.
๐Ÿ‘๏ธ0
Strukture Strukture 3 months ago
I was out at 8.20 on that push for a quick 30%
๐Ÿ‘๏ธ0
tw0122 tw0122 3 months ago
Gave you green light alert at $4s premarket ..lol on the monthly chart all green with 3 hits the 3rd being today 
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 3 months ago
mhmm
๐Ÿ‘๏ธ0
LowFloatLopes LowFloatLopes 3 months ago
Got a sale set at 9.70
๐Ÿ‘๏ธ0
LowFloatLopes LowFloatLopes 3 months ago
6.45 here :)
๐Ÿ‘๏ธ0
Strukture Strukture 3 months ago
Re loaded at 6.30 halted up back at HOD 8.40
๐Ÿ‘๏ธ0
ecmoney ecmoney 3 months ago
Halted again $8.39

Ec
๐Ÿ‘๏ธ0
LowFloatLopes LowFloatLopes 3 months ago
In at $4.30 out at $7.90 in 15 mins lol 
๐Ÿ‘๏ธ0
Strukture Strukture 3 months ago
CYCN Boom
๐Ÿ‘๏ธ0
ecmoney ecmoney 3 months ago
Halted at $6

Rc
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 3 months ago
CYCN: Could NOT find any PR's nor otherwise NEWS anywhere to support this??? (Just the MM machines & algos???)
๐Ÿ‘๏ธ0
ecmoney ecmoney 3 months ago
Thinking about jumping back in around $5


Ec
๐Ÿ‘๏ธ0
glenn1919 glenn1919 3 months ago
CYCN.....................................$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
๐Ÿ‘๏ธ0
ecmoney ecmoney 3 months ago
Iโ€™m out

Easy 300%

Ec
๐Ÿ‘๏ธ0
tw0122 tw0122 3 months ago
$6.43 + 300% going to cash out now 
๐Ÿ‘๏ธ0
tw0122 tw0122 3 months ago
$5.49'+ 250%
๐Ÿ‘๏ธ0
tw0122 tw0122 3 months ago
Party over here also $5.05 + 210%
๐Ÿ‘๏ธ0
tw0122 tw0122 3 months ago
CYCN $4.88 + 200% 
๐Ÿ‘๏ธ0
tw0122 tw0122 3 months ago
CYCN 2.62 +92% flip out time 
๐Ÿ‘๏ธ0
glenn1919 glenn1919 3 months ago
cycn.......................................................https://stockcharts.com/h-sc/ui?s=cycn&p=D&yr=0&mn=2&dy=12&id=p84071410134


...............................nice bounce & volume..................................................
๐Ÿ‘๏ธ0
tw0122 tw0122 3 months ago
2.49 +'83%
๐Ÿ‘๏ธ0
tw0122 tw0122 3 months ago
CYCN $2.26 + 70%
๐Ÿ‘๏ธ0
glenn1919 glenn1919 3 months ago
CYCN.................................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
glenn1919 glenn1919 4 months ago
CYCN.................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
tw0122 tw0122 4 months ago
$2.40- $2.65 first line of resistance breaks solid $3.16 next 
๐Ÿ‘๏ธ0
tw0122 tw0122 4 months ago
Mini pump
๐Ÿ‘๏ธ0
Banjo50 Banjo50 7 months ago
It should be five cents. I bid five cents.
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 8 months ago
CYCN: Closed up by 55% today (Etrade), but no posts here for months.
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock